MissionIR would like to highlight CytRx Corp. (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology. The company’s pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib.
In the company’s news,
Seeking Alpha yesterday published the following article featuring CytRx: http://seekingalpha.com/article/1700372-cytrx-corporation-remains-an-undiscovered-opportunity-inthe-cancer-space?source=yahoo#comments_header
Released On: 4/8/2016
Views: 3784
Released On: 4/7/2016
Views: 4530
Released On: 3/31/2016
Views: 3502
Released On: 3/24/2016
Views: 2866
Released On: 3/17/2016
Views: 2414
Released On: 3/11/2016
Views: 2236
Released On: 3/4/2016
Views: 2556
Released On: 3/3/2016
Views: 2256
Released On: 2/23/2016
Views: 3603
Released On: 2/12/2016
Views: 2588
Released On: 2/10/2016
Views: 2306
Released On: 2/9/2016
Views: 2457
Released On: 1/20/2016
Views: 4248
Released On: 1/14/2016
Views: 4711
Released On: 1/5/2016
Views: 2960
Released On: 12/18/2015
Views: 9269
Released On: 12/9/2015
Views: 2712
Released On: 12/3/2015
Views: 3153